Replies to post #30658 on Delcath Systems Inc (DCTH)

[Rapture2020]

Sam,

I do my homework, thank you very much. I also choose to ignore fools who hector me at every turn.

And Inaccurate speculation? What does that even mean? it's an internet message board about a biotech stock. If you are not an insider, it's all inaccurate speculation to one degree or another.

So let's switch gears:

You have stated time and time again FOCUS is the only important catalyst for DCTH. You don't think DCTH's Phase 2 Study on HCC, the most common primary cancer of the liver (700,000 new cases diagnosed worldwide annually), is important?

I do, and it's going to be completed in less than two weeks. I'm going to speculate that Jenny has parlayed these results to coincide with the upcoming offering. I have no concern as to whether she can get at least $.04 /share. At a minimum.

Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma:

1. Study Type : Interventional (Clinical Trial)
2. Estimated Enrollment : 42 participants
3. Allocation: Non-Randomized
4. Intervention Model: Parallel Assignment
5. Masking: None (Open Label)
6. Primary Purpose: Treatment
7. Official Title: An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
8. Study Start Date : June 2014
9. Estimated Primary Completion Date: December 2017
10. Estimated Study Completion Date: February 2018